A more certain answer in cases where the stakes of getting it wrong are high
Em um país onde 1,2 milhão de pessoas convivem com o Alzheimer, a chegada de um exame de sangue baseado em espectrometria de massa representa mais do que um avanço técnico — é uma tentativa de iluminar o que a mente começa a perder antes mesmo de perceber. Desenvolvido para detectar proteínas marcadoras da doença com precisão incomum, o teste oferece uma alternativa menos invasiva ao método tradicional de coleta de líquido cefalorraquidiano, abrindo caminho para diagnósticos mais seguros nos momentos em que a dúvida clínica tem consequências graves.
- O Alzheimer avança silenciosamente no Brasil, matando neurônios e memórias de 1,2 milhão de pessoas, com uma taxa de mortalidade de 25 óbitos por 100 mil habitantes.
- O diagnóstico tradicional depende de observação clínica e, quando necessário, de uma punção lombar — procedimento invasivo, caro e contraindicado para muitos pacientes.
- A espectrometria de massa resolve um problema técnico crucial: detectar concentrações mínimas de beta-amiloide no sangue, superando a barreira hematoencefálica que dilui as proteínas antes de chegarem à corrente sanguínea.
- O exame não é triagem universal — ele é reservado para casos de incerteza diagnóstica, especialmente quando o Alzheimer pode ser confundido com demência frontotemporal, cujo tratamento é incompatível com o da primeira condição.
- Lançado nos Estados Unidos pouco antes de chegar ao Brasil pela rede Dasa, o teste sinaliza uma transição: do diagnóstico baseado em sintomas para um ancorado em marcadores biológicos mensuráveis.
Um novo exame de sangue chegou ao Brasil com a promessa de tornar o diagnóstico do Alzheimer mais preciso e menos invasivo. Usando espectrometria de massa, a tecnologia detecta a proteína beta-amiloide — substância que se acumula no cérebro de pacientes com a doença — a partir de uma simples coleta sanguínea, sem a necessidade de punção lombar.
O Alzheimer afeta cerca de 1,2 milhão de brasileiros, correspondendo a 11% da população idosa, e responde por 25 mortes por 100 mil habitantes. A doença destrói progressivamente a memória e as funções cognitivas, resultado da morte neuronal provocada pelo acúmulo de beta-amiloide e pela retenção da proteína tau. Esses dois marcadores biológicos são hoje reconhecidos como sinais patológicos centrais da condição.
Até agora, observar essas proteínas exigia a extração de líquido cefalorraquidiano — um procedimento que requer médico treinado, tem custo elevado e apresenta contraindicações para pacientes com infecções cutâneas ou problemas na coluna. O novo exame contorna essas limitações, mas enfrenta um desafio próprio: as proteínas chegam ao sangue em quantidades muito menores do que no líquido espinhal. A espectrometria de massa resolve esse problema ao separar e medir moléculas com sensibilidade extraordinária, mesmo em concentrações mínimas.
O teste, no entanto, não é indicado para triagem em massa. O Alzheimer continua sendo, em essência, um diagnóstico clínico. O exame está reservado para situações de incerteza — sobretudo quando os sintomas do paciente podem indicar tanto Alzheimer quanto demência frontotemporal, duas doenças cujos tratamentos são incompatíveis entre si. Nesses casos, um marcador biológico preciso deixa de ser apenas útil e passa a ser decisivo.
A new blood test has arrived in Brazil with the potential to reshape how doctors diagnose Alzheimer's disease. The test uses advanced technology called mass spectrometry to detect tiny proteins in blood samples—specifically beta-amyloid, a substance that accumulates in the brains of people with Alzheimer's. It's a simpler, less invasive alternative to existing diagnostic methods, and it comes at a moment when the disease is quietly devastating millions across the country.
Alzheimer's affects roughly 1.2 million Brazilians, striking about 11 percent of the elderly population. The disease erodes memory and the ability to perform everyday tasks, a consequence of progressive damage to the central nervous system. According to global health data from 2019, Alzheimer's and related dementias account for 25 deaths per 100,000 people in Brazil. The diagnosis has traditionally relied on clinical observation—a doctor evaluates symptoms and imaging results to determine whether a patient actually has the disease. But this approach has limitations, and researchers have spent years trying to understand the biological mechanisms that could make diagnosis more precise.
Scientists have identified two proteins as reliable markers of Alzheimer's. The first is beta-amyloid, which normally exists on the surfaces of neurons, the cells essential to brain function. Rodrigo Carvalho, a neurologist at DFVNeuro and Hospital Sírio-Libanês, explains that when beta-amyloid accumulates in excess, it begins to deposit itself in brain tissue—a process that may start years before symptoms appear. This buildup triggers the retention of a second protein called tau, which causes neurons to die and sets off a cascade of brain degeneration. Both proteins are now understood as pathological markers, and the field is moving toward classifying Alzheimer's based on these altered substances rather than symptoms alone.
Until now, doctors could observe these markers through cerebrospinal fluid collection—a procedure in which a physician inserts a needle between the vertebrae of the spine to extract fluid that bathes the brain and spinal cord. Because this fluid is in constant contact with the nervous system, it contains higher concentrations of beta-amyloid, making it useful for diagnosis. Lower concentrations of the protein in the fluid suggest the substance is trapped in the brain's tissue, pointing toward Alzheimer's. But the procedure is expensive, requires a trained physician, and carries contraindications for patients with skin infections or spinal problems that make needle insertion difficult.
The new blood test, launched in the United States just over a month before arriving in Brazil through the Dasa hospital and laboratory network, attempts to overcome these obstacles. It works on the same principle—measuring beta-amyloid to determine if a patient has Alzheimer's—but it requires a simple blood draw. The challenge is that proteins pass from cerebrospinal fluid into the bloodstream in much smaller quantities, a phenomenon called the blood-brain barrier. A standard blood test would lack the precision to detect such minute amounts. Mass spectrometry solves this problem. As Gustavo Campana, Dasa's medical director, explains, the technology allows doctors to separate different molecules and measure their concentrations with extraordinary sensitivity, even when present in tiny quantities.
But this test is not for everyone. Alzheimer's remains fundamentally a clinical diagnosis, one that depends on the doctor's evaluation and other investigative tools like MRI scans to rule out conditions that mimic Alzheimer's, such as stroke. The blood test is reserved for specific cases—particularly when a doctor suspects a patient might have either Alzheimer's or frontotemporal dementia, another neurodegenerative disease. This distinction matters because the treatment for Alzheimer's can actually worsen frontotemporal dementia. In such diagnostic dilemmas, a precise biological marker becomes not just helpful but essential. The test represents a step toward more certain answers in cases where the stakes of getting it wrong are high.
Citações Notáveis
The protein deposit may begin years before Alzheimer's symptoms appear, establishing it as a pathological marker of the disease— Rodrigo Carvalho, neurologist at DFVNeuro and Hospital Sírio-Libanês
The technology allows separation of different molecules to observe their concentration in a blood sample— Gustavo Campana, medical director of Dasa
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this test arrived now, in Brazil specifically?
Because 1.2 million Brazilians have Alzheimer's, and most of them are being diagnosed the old way—through clinical observation alone. A doctor watches for memory loss, orders an MRI, and makes a judgment call. This test gives them a biological fact to anchor that judgment.
But you said it's not for everyone. So who actually gets it?
Doctors use it when they're genuinely uncertain—when a patient's symptoms could be Alzheimer's or could be frontotemporal dementia. Those two diseases look similar but need different treatments. Getting it wrong can harm the patient.
Why is the blood test better than the spinal tap they've been doing?
The spinal tap works well, but it's expensive, it requires a specialist to do it, and some patients can't have it done at all—people with skin infections or spine problems. A blood draw is simple, cheap, and almost anyone can have it.
How does the technology actually work if the protein is barely present in blood?
Mass spectrometry is extraordinarily precise. It can separate molecules and measure them even when they're present in tiny amounts. The protein does leak from the brain into the blood, just in small quantities. The machine can still detect it.
What happens next? Will everyone get this test?
No. It will be used strategically, in cases where clinical diagnosis isn't clear enough. The goal isn't to screen everyone—it's to give doctors a more certain answer when the stakes of being wrong are high.
Does this cure Alzheimer's?
No. It's a diagnostic tool. But a more certain diagnosis earlier means patients can start treatment sooner, and doctors can avoid treating the wrong disease.